Article Figures & Data
Figures
- FIGURE 1.
Overview of synthesized FAPI derivatives. EC50 obtained by competition experiments is shown for selected compounds. §Discussed in previous publication (28). *ε-amine modified by DOTA. **Cysteine-thiol attached to maleimide-carrying piperazinylpropoxy moiety. n.d. = not determined.
- FIGURE 2.
Relative binding and internalization rates of 177Lu-labeled FAPI derivatives compared with FAPI-02 (set to 100%) on FAP-expressing HT-1080 cells at 1 h (A), 4 h (B), and 24 h (C) after radiotracer administration.
- FIGURE 3.
(A–C) Biodistribution of selected FAPI derivatives in HT-1080 FAP xenografts at 1 h (A), 4 h (B), and 24 h (C) after radiotracer administration. (D) Tumor uptake of selected compounds.
- FIGURE 4.
PET imaging of FAPI-04 in mice bearing SK-LMS-1 and HT-1080 FAP tumors, along with corresponding time–activity curves.
- FIGURE 5.
PET imaging of FAPI-04 in HT-1080 FAP tumor-bearing mice with and without simultaneous injection of unlabeled FAPI-04 as competitor, along with corresponding time–activity curves.
- FIGURE 6.
PET maximum-intensity projections of patient with metastasized breast cancer 10 min, 1 h, and 3 h after administration of 263 MBq of 68Ga-FAPI-04. Activity is seen in renal pelvis, bladder, and metastases. Normal organs show low uptake resulting in high image contrast.
- FIGURE 7.
(A) PET maximum-intensity projection of patient with metastasized breast cancer 1 h after administration of 270 MBq of 68Ga-FAPI-04. Robust uptake is seen in metastases. (B) Bremsstrahlung images showing uptake at 3 h and even 1 d after treatment with 90Y-FAPI-04 in same patient.
Additional Files
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- {alpha}v{beta}6-Targeted Molecular PET/CT Imaging of the Lungs After SARS-CoV-2 Infection
- Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-Labeled FAP Inhibitor
- Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging
- Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy
- Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography
- The Role of 68Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience
- Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
- Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models
- FAP: The Next Billion Dollar Nuclear Theranostics Target?
- Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04
- A Conversation Between Uwe Haberkorn and Johannes Czernin
- Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention
- Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
- The Future of Nuclear Medicine as an Independent Specialty
- Novel Structured Reporting Systems for Theranostic Radiotracers
- 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers